N
INBX icon

Natixis’s Inhibrx INBX Stock Holding History

Natixis’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-889
Closed -$70.2K – 1219
2025
Q4 		$70.2K Sell
889
-1,111
-56% -$75.7K ﹤0.01% 988
2025
Q3 		$67.4K Hold
2,000
– – ﹤0.01% 921
2025
Q2 		$28.5K Hold
2,000
– – ﹤0.01% 915
2025
Q1 		$27.5K Hold
2,000
– – ﹤0.01% 854
2024
Q4 		$30.8K Hold
2,000
– – ﹤0.01% 916
2024
Q3 		$31.3K Hold
2,000
– – ﹤0.01% 806
2024
Q2 		$28.3K Buy
+2,000
New +$31.2K ﹤0.01% 806

Other funds holding INBX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Natixis's INBX Position: Q1 2026 in Review

Natixis sold out of Inhibrx (INBX) in Q1 2026, closing a stake of 889 shares — an estimated $70.2K sold.

Natixis first reported a position in INBX in Q2 2024 and held it in 7 quarters. The position peaked at $70.2K in Q4 2025. 135 funds tracked by Wall St. Rank hold INBX as of Q1 2026.

  • Natixis reported no remaining Inhibrx position as of Q1 2026 after selling out during the quarter.
  • Natixis sold 889 Inhibrx shares in Q1 2026, an estimated $70.2K.
  • Natixis first reported a position in Inhibrx in Q2 2024 and held it in 7 quarters.
  • Natixis's Inhibrx position peaked at $70.2K in Q4 2025.
  • 135 funds tracked by Wall St. Rank held Inhibrx as of Q1 2026.

Based on Natixis's 13F filing for Q1 2026, filed 14 May 2026.